At the same time, the Vigil vaccine, based on autologous cancer cells expressing GM-CSF and inhibiting furin, has shown encouraging results in recurrent ovarian cancer patients with tumors expressing PD-L1 in a phase I/II study, giving a benefit in PFS in combination with durvalumab [84,85,87]. This evidence concerns the gene CSF2 and ovarian cancer.